Morgan Stanley’s CapForce IBD Breakout Opportunities ETF BOUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1
Closed -$47 8317
2025
Q4
$47 Sell
1
-1
-50% -$37 ﹤0.01% 7875
2025
Q3
$85 Hold
2
﹤0.01% 7713
2025
Q2
$79 Hold
2
﹤0.01% 7682
2025
Q1
$79 Buy
2
+1
+100% +$39 ﹤0.01% 7613
2024
Q4
$45 Hold
1
﹤0.01% 7644
2024
Q3
$57 Hold
1
﹤0.01% 7541
2024
Q2
$58 Buy
+1
New +$35 ﹤0.01% 7453
2022
Q3
Sell
-2,000
Closed -$60K 7709
2022
Q2
$60K Hold
2,000
﹤0.01% 6525
2022
Q1
$76K Hold
2,000
﹤0.01% 6480
2021
Q4
$77K Hold
2,000
﹤0.01% 6579
2021
Q3
$69K Hold
2,000
﹤0.01% 6564
2021
Q2
$67K Hold
2,000
﹤0.01% 6534
2021
Q1
$66K Hold
2,000
﹤0.01% 6215
2020
Q4
$63K Hold
2,000
﹤0.01% 6079
2020
Q3
$47K Hold
2,000
﹤0.01% 5742
2020
Q2
$44K Hold
2,000
﹤0.01% 5720
2020
Q1
$37K Hold
2,000
﹤0.01% 5569
2019
Q4
$42K Hold
2,000
﹤0.01% 5903
2019
Q3
$39K Buy
+2,000
New +$41.8K ﹤0.01% 5813

Other funds holding BOUT

Morgan Stanley's BOUT Position: Q1 2026 in Review

Morgan Stanley sold out of CapForce IBD Breakout Opportunities ETF (BOUT) in Q1 2026, closing a stake of 1 share — an estimated $47 sold.

Morgan Stanley first reported a position in BOUT in Q3 2019 and held it in 19 quarters. The position peaked at $77K in Q4 2021. 14 funds tracked by Wall St. Rank hold BOUT as of Q1 2026.

  • Morgan Stanley reported no remaining CapForce IBD Breakout Opportunities ETF position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 1 CapForce IBD Breakout Opportunities ETF share in Q1 2026, an estimated $47.
  • Morgan Stanley first reported a position in CapForce IBD Breakout Opportunities ETF in Q3 2019 and held it in 19 quarters.
  • Morgan Stanley's CapForce IBD Breakout Opportunities ETF position peaked at $77K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held CapForce IBD Breakout Opportunities ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.